0
0
1/22/23 at 4:25pm
Organization
Nikkei.com
Author
Staff Writer
23 words
0
Comments
Leqembi's price point spurs optimism after Aduhelm, but wide use unclear
You are the first to view
https://asia.nikkei.com/Business/Pharmaceuticals/Eisai-s-new-Alzheimer-s-drug-divides-market-watchers
Create an account
or login to join the discussion